Enhancement of antitumor activity of 5-fluorouracil by ribothymidine.
The antitumor activity of 5-fluorouracil (5-FU) in combination with ribothymidine was examined on some experimental murine carcinomas. The antitumor activity of 5-FU against Ehrlich ascites carcinoma was markedly enhanced by intraperitoneal coadministration of ribothymidine. The enhancement of the antitumor activity of 5-FU by ribothymidine was also observed against Ehrlich solid carcinoma both by oral and intraperitoneal administrations. Furthermore, the combination therapy of 5-FU and ribothymidine was effective even on 5-FU-resistant P388 leukemia. These results suggest that the combination of 5-FU and ribothymidine may be more effective than 5-FU monotherapy in clinical use.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D004357:Drug Synergism; D005472:Fluorouracil / Q000008:administration & dosage / Q000494:pharmacology*; D007941:Leukemia P388 / Q000188:drug therapy; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D014529:Uridine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
C009182:ribothymidine; D005472:Fluorouracil; D014529:Uridine